ArticleFrontiers in pharmacology2025
Scutellarin attenuates hypoxia-induced retinal neovascularization through bidirectional modulation of the VEGF/Ang/Tie2 pathway.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Scutellarin attenuates high glucose-induced edema and inflammation in retinal Müller cells via AQP4/Kir4.1 restoration and TLR4/MyD88/NF-κB inhibition.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Scutellarin (SCU), a flavonoid with established pharmacological activity, exhibits anti-angiogenic and vascular-stabilizing effects in ischemic ocular diseases. Methods: This study investigated its bidirectional modulation of the vascular endothelial growth factor(VEGF)/Angiopoietin (Ang)/Tie2 signaling pathway in retinal neovascularization (RNV) under hypoxic conditions and compared its efficacy with Faricimab, a dual-target angiogenesis inhibitor. A CoCl Results: SCU significantly and dose-dependently suppressed rRMEC proliferation, migration, and tube formation under hypoxia, with effects comparable to those of Faricimab at higher concentrations. Network pharmacology identified 43 overlapping targets between SCU and RNV. Pathway enrichment analysis indicated involvement of VEGF, MAPK, and Ras signaling. Molecular docking showed strong binding of SCU to VEGF-A, Ang2, Tie2, and Vascular endothelial protein tyrosine phosphatase (VE-PTP). SCU downregulated pro-angiogenic factors (VEGF-A, Ang2, HIF-1α, VE-PTP) and upregulated vascular stability-related proteins (Ang1, Tie2, vascular endothelial cadherin (VE-cadherin)) at both mRNA and protein levels. Discussion: These results suggest that SCU exerts a dual regulatory effect on retinal neovascularization by simultaneously inhibiting pathological angiogenesis and enhancing vascular stabilization via the VEGF/Ang/Tie2 signaling pathway. Its mode of action complements and extends the mechanism of Faricimab, supporting its potential as a promising natural candidate for retinal vascular disease therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.